Anti-Glycan related Enzyme Antibody Development Services

We develop antibodies against fucosyltransferases (α1,2-, α1,3/4-, α1,6-) using catalytic/luminal-domain antigens and isoform-unique motifs. Homolog counterscreens drive specificity for closely related family members in cell lysates and FFPE tissues.

Antigen designs derive from catalytic regions or isoform-specific insertions of β1,4- and β1,3-galactosyltransferases, with glyco-mimetic decoys to shape epitope focus. Matrix-aware screening supports reliable use in Western blot, IHC, and flow cytometry.

We design lipid-presenting immunogens and peptide–liposome constructs that preserve native UGCG conformation. Discovery incorporates detergent/liposome screening to maintain epitope accessibility in cells and tissues.

Targets include mannosyltransferases in N-glycan and O-mannose pathways using luminal/catalytic fragments and paralog-separating motifs. Cross-family counterscreens enhance selectivity for pathway mapping and mechanistic studies.

We generate antibodies to MGAT-family N-acetylglucosaminyltransferases from catalytic cores and isoform-specific loops. Selection emphasizes isoform discrimination and compatibility with standard cell and tissue workflows.

We create antibodies against α2,3-, α2,6-, and α2,8-sialyltransferases using antigens that capture family signatures while avoiding conserved motifs. Homolog-panel counterscreening and substrate-analog decoys guide precise specificity.

Isoform-focused development for UGT families uses luminal/catalytic domains and unique variable regions to separate UGT1A from UGT2B members. Microsome-informed screening strengthens recognition in hepatic and extrahepatic contexts.

We develop antibodies to O-GalNAc transferases (GALNT1–20) using luminal/catalytic fragments and glycopeptide-mimetic immunogens to capture physiologically relevant epitopes.

Optimize protein glycosylation—via cell-line engineering, process control, or chemoenzymatic remodeling—to boost potency, stability, and half-life. Applicable to enzymes, cytokines, and Fc-fusions; options include targeted sialylation, galactosylation, defucosylation, or bisecting GlcNAc. Delivered as glycoform-verified variants with application-aligned analytics (research use only).

Tune IgG Fc glycans—afucosylation, galactosylation, or sialylation—to modulate ADCC/CDC and pharmacokinetics. Implemented through host edits and process optimization with optional enzymatic remodeling; variants are confirmed by glycoanalytics and effector-function assays (research use only).